As global leaders in conducting Phase II to III human challenge and vaccine trials in infectious and respiratory diseases, we bring unmatched expertise in virology and vaccine development. Our streamlined approach accelerates timelines through rapid recruitment, expert-led study design, and dedicated clinical and operational resources.
We also have advanced capabilities in primary care research, with a strong emphasis on respiratory and airway diseases. A robust participant database ensures access to volunteers with relevant conditions, and the team is highly proficient in conducting spirometry, lung function tests, bronchial challenge tests, and other specialised respiratory assessments.
Our new Canary Wharf facility expands both inpatient and outpatient capacity. With 50 beds, the site supports standalone or multi-site Phase II/III trials, depending on sample size and population.
In addition to the facilities in the UK, we have two clinical research units in Germany.
Our Mannheim site has a long-standing track record of conducting a wide range of clinical trials, including proof-of-concept Phase IIa trials. The unit excels in cardiometabolic research, covering obesity, diabetes, metabolic disorders, and cardiovascular disease. In addition, this clinical research unit has an outpatient area that accommodates up to 200 trial participants without interrupting in-house activities.
Our Kiel site specialises in renal and hepatic impairment trials, focusing on small-to-mid-sized studies with complex pharmacokinetic and pharmacodynamic assessments.
Sign up to our emails and follow us on social media to keep up to date with hVIVO.
